Related Experiment Videos
Recent advances in statins and the kidney
1Department of Medicine, Hennepin County Medical Center, Minneapolis, Minnesota, USA.
Kidney International. Supplement
|July 21, 1999
Summary
Statins and lipid-lowering drugs reduce serum lipids and may also combat kidney disease progression by targeting inflammation and fibrosis pathways. These agents impact cellular signaling, offering potential benefits beyond lipid reduction for renal health.
Area of Science:
- Nephrology
- Pharmacology
- Cell Biology
Background:
- Dyslipidemia is linked to renal disease progression, with apolipoprotein B lipoproteins as a risk factor.
- Lipid-lowering interventions show promise in experimental models of kidney disease.
- Statins may possess anti-inflammatory properties beneficial for renal disease.
Purpose of the Study:
- To review in vivo and in vitro studies on statin mechanisms in renal disease.
- To present new research on novel cellular mechanisms of statin action.
- To explore how lipid-lowering agents impact renal pathology beyond lipid reduction.
Main Methods:
- Review of existing in vivo and in vitro studies on statin effects.
- Inclusion of novel research investigating cellular mechanisms.
- Analysis of studies focusing on anti-inflammatory and anti-fibrotic effects.
Main Results:
- Lipid-lowering agents modulate intracellular signaling, affecting cell proliferation and inflammation (macrophage adhesion, recruitment, maturation).
- These agents impact fibrogenesis, potentially influencing glomerulosclerosis and interstitial fibrosis.
- Effects are linked to intracellular nonsterol isoprenoid synthesis and protein prenylation in cell signaling.
Conclusions:
- Statins offer benefits beyond serum lipid reduction.
- They influence intracellular inflammatory and fibrogenic pathways.
- These actions are relevant to mitigating progressive renal injury.